Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.
about
Shiga toxin 2 targets the murine renal collecting duct epitheliumDo the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?The Crystal Structure of Shiga Toxin Type 2 with Bound Disaccharide Guides the Design of a Heterobifunctional Toxin InhibitorTargeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxinsAdministration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect.Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coliA glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2.Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.Shiga toxin pathogenesis: kidney complications and renal failure.Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.A novel murine infection model for Shiga toxin-producing Escherichia coli.Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodiesShiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complementDirect acute tubular damage contributes to Shigatoxin-mediated kidney failure.Serum Shiga toxin 2 values in patients during acute phase of diarrhoea-associated haemolytic uraemic syndrome.Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2Role of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage.Shiga toxin binding to glycolipids and glycans.Mouse models of Escherichia coli O157:H7 infection and shiga toxin injectionDysregulated autophagy contributes to podocyte damage in Fabry's disease.Shiga toxin subtypes display dramatic differences in potencyComparisons of native Shiga toxins (Stxs) type 1 and 2 with chimeric toxins indicate that the source of the binding subunit dictates degree of toxicity.Glycolipid binding preferences of Shiga toxin variants.Pro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular PatternsStructure-dependent pseudoreceptor intracellular traffic of adamantyl globotriaosyl ceramide mimicsVerotoxin A subunit protects lymphocytes and T cell lines against X4 HIV infection in vitro.Shiga Toxin (Stx) Type 1a Reduces the Oral Toxicity of Stx Type 2aAB5 Preassembly Is Not Required for Shiga Toxin Activity.Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease.Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10.Shiga toxin and its use in targeted cancer therapy and imagingSerum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamerProtection against Shiga ToxinsGlycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2.Shiga toxin of enterohaemorrhagic Escherichia coli directly injures developing human erythrocytes.Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.
P2860
Q24652310-A053782E-EB4C-4CAC-A5BF-91C659F1B8A1Q26858938-D5A72F2D-3EDA-4E2C-AD70-51B0EE5196EBQ27680604-2254DD39-FDB7-48FE-9CDD-5ABB0D598666Q28592771-0EC62BD4-F554-4590-A732-68F5C62E235DQ33364401-6E07064E-A459-4A05-A606-DCB9CF8AE231Q33380705-22D6FEFB-F465-41FD-B7A8-4B37C740583DQ33382197-89E0A688-5690-4105-8FB0-2767EC790468Q33387236-C6A8BBBB-1354-4602-B343-BD8F19E2DE99Q33388849-D11704D7-08A7-4FEF-8DD4-79CC46178C4EQ33393854-F4313734-E415-49A7-9941-3EB05CC2D0BEQ33394010-E964F82C-3491-4A95-94C6-198ED9386004Q33397541-27DC1087-F202-427A-98A0-982D1F6C6F12Q33401560-FA775468-06A5-4DFE-99F9-DFA22D39452AQ33403695-0708F0B9-F0F5-44B0-B132-2261FCA7CAA5Q33409030-84297CCF-389B-49E2-9882-B7E131F70C9BQ33411089-F15336F4-EF9D-4E93-B192-857A6DC00983Q33413591-22F9DF93-442C-42E4-AA37-A3794992E8F7Q33415795-8B203D2A-AC73-4E7F-8D72-F94F55DC6165Q33425759-1B771ED8-DF77-4262-A4B0-DB03AD5D94B8Q33801217-E7A200B1-E72A-47B7-A39C-1A7150B640EEQ34119320-2BE6180D-9AC1-43A1-B562-8FACB6E46851Q34163196-3D3E0279-E9BE-4360-A3DA-3763FAA52CA0Q34497115-D911556A-26A6-4D41-BD93-27B33D6DD509Q34730562-CEE3325D-9C02-493E-BC11-E189729FF456Q34739913-A2C113DE-B59C-4AD8-8E7A-24244FF1873BQ35132357-94D45ACD-803D-41E6-81A8-770BA2A4F0A8Q35199053-87E65796-8331-49E0-BBAE-641BA70BBB5FQ35295605-6C02E2EB-0A2C-4EB9-8986-EB884A00581AQ35956792-DCB62F8A-6BC1-4DE1-8BD9-7AF85495B98EQ36482722-424E8142-ACF9-4A6D-B7F6-031D964F6139Q36705833-C5CBFF2E-BE52-401A-BCFE-52F8DB8951F7Q37122525-942106FC-E1D5-4DFB-B785-658373881492Q37293251-D68F664D-BDF9-4D80-AB20-030BDFAF9917Q37643869-8165EC4D-7870-4819-8FC0-CD77B75E84EFQ37831422-B4AFBCF6-4127-42EA-BBEE-FAD89A42335AQ38350273-89B4C1B3-1498-4C6E-AAB7-07C35B12BCBBQ39122055-85A5EDA6-B67B-4BE9-AEC3-5397607017B9Q39673895-9729003D-4FDC-4821-8FD5-2E13A78025A5Q40750555-ED4C19B2-2752-47B0-A981-EE8DFFEF5EA2Q42913459-386AC548-5437-43D7-B952-ED2277992877
P2860
Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Differential tissue targeting ...... d 2 in the mouse animal model.
@ast
Differential tissue targeting ...... d 2 in the mouse animal model.
@en
type
label
Differential tissue targeting ...... d 2 in the mouse animal model.
@ast
Differential tissue targeting ...... d 2 in the mouse animal model.
@en
prefLabel
Differential tissue targeting ...... d 2 in the mouse animal model.
@ast
Differential tissue targeting ...... d 2 in the mouse animal model.
@en
P2093
P1433
P1476
Differential tissue targeting ...... d 2 in the mouse animal model.
@en
P2093
Beth A Binnington
Charles R Smith
Clifford A Lingwood
Mark D Maloney
Niels W P Rutjes
P304
P356
10.1046/J.1523-1755.2002.00502.X
P407
P577
2002-09-01T00:00:00Z
P5875
P6179
1041009585